** U.S.-listed shares of Israel-based drug developer PolyPid PYPD.O fell 4.7% to $2.75
** Company, which develops therapies to improve surgical outcomes, posts quarterly loss of $1.13 per share vs analysts' estimate loss of 88 cents
** Says independent monitoring board recommended to conclude late-stage study of experimental drug upon enrollment of 800 patients
** PYPD is testing the treatment to prevent surgical site infections in patients undergoing a type of abdominal cancer surgery
** Expects to report data from the late-stage in the second quarter of 2025 and plans to submit a marketing application to the FDA if the study meets the main goal
** In the last 12 months, stock has fallen 48.7%
(Reporting by Siddhi Mahatole)
((Siddhiprabhanjan.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。